Alaunos Therapeutics, Inc. Other Noncash Income (Expense)
Alaunos Therapeutics, Inc. (TCRT) reported Other Noncash Income (Expense) of $11.96 million for the 124-month period ending 2013-12-31, per its 10-K filed 2014-03-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2014-03-03
- Alaunos Therapeutics, Inc. other noncash income (expense) for the quarter ending 2013-12-31 was -$1.79M, a 120.94% decline year-over-year.
- Alaunos Therapeutics, Inc. other noncash income (expense) for the quarter ending 2013-09-30 was -$7.41M, a 287.73% decline year-over-year.
- Alaunos Therapeutics, Inc. other noncash income (expense) for the quarter ending 2013-06-30 was -$403.00K.
- Alaunos Therapeutics, Inc. other noncash income (expense) for the quarter ending 2013-03-31 was $10.79M.
- Alaunos Therapeutics, Inc. other noncash income (expense) for fiscal 2013 was $1.19M, a 80.41% decline from fiscal 2012.
- Alaunos Therapeutics, Inc. other noncash income (expense) for fiscal 2012 was $6.05M, a 20.22% decline from fiscal 2011.
- Alaunos Therapeutics, Inc. other noncash income (expense) for fiscal 2011 was $7.58M.
- Alaunos Therapeutics, Inc. other noncash income (expense) for fiscal 2010 was -$8.89M, a 299.26% decline from fiscal 2009.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 85 month | Other Noncash Income (Expense) 94 month | Other Noncash Income (Expense) 97 month | Other Noncash Income (Expense) 100 month | Other Noncash Income (Expense) 103 month | Other Noncash Income (Expense) 106 month | Other Noncash Income (Expense) 109 month | Other Noncash Income (Expense) 112 month | Other Noncash Income (Expense) 115 month | Other Noncash Income (Expense) 118 month | Other Noncash Income (Expense) 121 month | Other Noncash Income (Expense) 124 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013-12-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$9.20M derived: sum of 2 quarters · filed 2014-03-03 | -$9.60M derived: sum of 3 quarters · filed 2014-03-03 | $1.19M 10-K · filed 2014-03-03 | $11.96M 10-K · filed 2014-03-03 | ||||||||||||
| 2013-09-30 | -$7.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-22 | -$7.81M derived: sum of 2 quarters · filed 2013-10-22 | $2.98M 10-Q · filed 2013-10-22 | $11.54M derived: sum of 4 quarters · filed 2014-03-03 | $13.75M 10-Q · filed 2013-10-22 | ||||||||||||
| 2013-06-30 | -$403.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $10.38M 10-Q · filed 2013-08-08 | $18.95M derived: sum of 3 quarters · filed 2014-03-03 | $22.90M derived: sum of 4 quarters · filed 2014-03-03 | $21.16M 10-Q · filed 2013-08-08 | ||||||||||||
| 2013-03-31 | $10.79M 10-Q · filed 2013-05-07 | $19.35M derived: sum of 2 quarters · filed 2014-03-03 | $23.30M derived: sum of 3 quarters · filed 2014-03-03 | $22.65M derived: sum of 4 quarters · filed 2014-03-03 | $21.56M 10-Q · filed 2013-05-07 | ||||||||||||
| 2012-12-31 | $8.57M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $12.51M derived: sum of 2 quarters · filed 2014-03-03 | $11.86M derived: sum of 3 quarters · filed 2014-03-03 | $6.05M 10-K · filed 2014-03-03 | $10.77M 10-K · filed 2013-03-18 | ||||||||||||
| 2012-09-30 | $3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-22 | $3.29M derived: sum of 2 quarters · filed 2013-10-22 | -$2.52M 10-Q · filed 2013-10-22 | $2.52M 10-Q · filed 2012-11-08 | $9.49M derived: sum of 4 quarters · filed 2014-03-03 | -$2.21M 10-Q · filed 2012-11-08 | |||||||||||
| 2012-06-30 | -$650.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$6.46M 10-Q · filed 2013-08-08 | $5.54M derived: sum of 3 quarters · filed 2014-03-03 | $10.09M derived: sum of 4 quarters · filed 2014-03-03 | -$1.74M 10-Q/A · filed 2012-08-28 | ||||||||||||
| 2012-03-31 | -$5.81M 10-Q · filed 2013-05-07 | $6.20M derived: sum of 2 quarters · filed 2014-03-03 | $10.74M derived: sum of 3 quarters · filed 2014-03-03 | $12.85M derived: sum of 4 quarters · filed 2014-03-03 | -$1.09M 10-Q · filed 2012-05-03 | ||||||||||||
| 2011-12-31 | $12.01M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $16.55M derived: sum of 2 quarters · filed 2014-03-03 | $18.66M derived: sum of 3 quarters · filed 2014-03-03 | $7.58M 10-K · filed 2014-03-03 | $4.72M 10-K · filed 2012-02-29 | ||||||||||||
| 2011-09-30 | $4.54M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-08 | $6.66M derived: sum of 2 quarters · filed 2012-11-08 | -$4.42M 10-Q · filed 2012-11-08 | $4.42M 10-Q · filed 2011-11-03 | -$10.65M derived: sum of 4 quarters · filed 2013-03-18 | $1.56M 10-Q · filed 2011-11-03 | |||||||||||
| 2011-06-30 | $2.12M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-08-28 | -$8.96M 10-Q/A · filed 2012-08-28 | -$15.19M derived: sum of 3 quarters · filed 2013-03-18 | -$18.90M derived: sum of 4 quarters · filed 2013-03-18 | -$11.83M 10-Q/A · filed 2011-08-09 | ||||||||||||
| 2011-03-31 | -$11.08M 10-Q · filed 2012-05-03 | -$17.31M derived: sum of 2 quarters · filed 2013-03-18 | -$21.02M derived: sum of 3 quarters · filed 2013-03-18 | ||||||||||||||
| 2010-12-31 | -$6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$9.94M derived: sum of 2 quarters · filed 2013-03-18 | -$8.89M 10-K · filed 2013-03-18 | ||||||||||||||
| 2010-09-30 | -$3.71M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-03 | -$2.66M 10-Q · filed 2011-11-03 | $3.37M 10-Q · filed 2011-08-01 | ||||||||||||||
| 2010-06-30 | $1.05M 10-Q/A · filed 2011-08-09 | ||||||||||||||||
| 2009-12-31 | $4.98M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $4.46M 10-K · filed 2012-02-29 | |||||||||||||||
| 2009-09-30 | -$520.00K 10-Q · filed 2011-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |